Chris Howerton analyst JEFFERIES

Currently out of the existing stock ratings of Chris Howerton, 102 are a BUY (75.56%), 29 are a HOLD (21.48%), 4 are a SELL (2.96%).

Chris Howerton

Work Performance Price Targets & Ratings Chart

Analyst Chris Howerton, currently employed at JEFFERIES, carries an average stock price target met ratio of 56.48% that have a potential upside of 37.18% achieved within 272 days.

Chris Howerton’s has documented 275 price targets and ratings displayed on 44 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AVDL, Avadel Pharmaceuticals PLC at 22-Oct-2025.

Wall Street Analyst Chris Howerton

Analyst best performing recommendations are on PSTI (PLURISTEM).
The best stock recommendation documented was for PSTI (PLURISTEM) at 12/10/2020. The price target of $6 was fulfilled within 1 day with a profit of $0.22 (3.54%) receiving and performance score of 35.37.

Average potential price target upside

ACAD ACADIA Pharmaceuticals AMTI Applied Molecular Transport  AXSM Axsome Therapeutics BTAI BioXcel Therapeutics GMTX Gemini Therapeutics IMMU Immunomedics KRTX Karuna Therapeutics MCRB Seres Therapeutics PSTI Pluristem TGTX TG Therapeutics TXMD TherapeuticsMD VERU Veru VNDA Vanda Pharmaceuticals CARA Cara Therapeutic SPPI Spectrum Pharmaceuticals APLS Apellis Pharmaceuticals ARDX Ardelyx ARNA Arena Pharmaceuticals AVDL Avadel Pharmaceuticals PLC CLDX Celldex Therapeutics EVLO Evelo Biosciences HRMY Harmony Biosciences Holdings IGMS IGM Biosciences MEIP MEI Pharma AVTX Avalo Therapeutics FNCH Finch Therapeutics Group ISEE IVERIC bio LABP Landos Biopharma PNT POINT Biopharma Global TCRT Alaunos Therapeutics ZIOP ZIOPHARM Oncology PRVB Provention Bio KDMN Kadmon Holdings CGEN Compugen CORT Corcept Therapeutics IOBT IO Biotech LQDA Liquidia Technologies MIST Milestone Pharmaceuticals PTGX Protagonist Therapeutics URGN UroGen Pharma Ltd VRDN Viridian Therapeutics GPCR Structure Therapeutics American Depositary Shares NERV Minerva Neurosciences SESN Sesen Bio

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 08-Dec-2021

$23

$-0.99 (-4.13%)

$22

17 days ago
(06-Feb-2026)

17/17 (100%)

$-0.56 (-2.38%)

84

Buy Since 26-Jun-2025

$31

$7.01 (29.22%)

$32

20 days ago
(03-Feb-2026)

0/5 (0%)

$6.24 (25.20%)

Buy Since 21-Oct-2025

$36

$12.01 (50.06%)

$33

1 months 17 days ago
(06-Jan-2026)

0/2 (0%)

$9.06 (33.63%)

Buy Since 17-Oct-2023

$40

$16.01 (66.74%)

$39

1 months 17 days ago
(06-Jan-2026)

2/7 (28.57%)

$13.06 (48.48%)

467

Hold Since 03-Nov-2022

$25

$1.01 (4.21%)

2 months 12 days ago
(11-Dec-2025)

18/21 (85.71%)

$-1.68 (-6.30%)

118

Show more analysts

Please expand the browser size to see the chart

Which stock is Chris Howerton is most bullish on?

Potential upside of $-1.64 has been obtained for AVDL (AVADEL PHARMACEUTICALS PLC)

What Year was the first public recommendation made by Chris Howerton?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?